3,833
Views
3
CrossRef citations to date
0
Altmetric
COVID-19

Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective

, , , , , , , & show all
Pages 160-171 | Received 08 Oct 2021, Accepted 13 Jan 2022, Published online: 10 Feb 2022

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.